Blackhawk Capital Partners Llc. Bristol Myers Squibb CO Transaction History

Blackhawk Capital Partners Llc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 04, 2020	SELL	$54.82 - $64.09 $2.24 Million - $2.62 Million	-40,870 Closed	0 $0
Q1 2020 Apr 03, 2020	SELL	$46.4 - $67.43 $27,190 - $39,513	-586 Reduced 1.41%	40,870 $2.62 Million
Q4 2019 Feb 07, 2020	BUY	$49.21 - $64.19 $10,383 - $13,544	211 Added 0.51%	41,456 $2.1 Million
Q3 2019 Nov 08, 2019	BUY	$42.77 - $50.71 $48,757 - $57,809	1,140 Added 2.84%	41,245 $2.09 Million
Q2 2019 Aug 13, 2019	BUY	$44.62 - $49.34 $185,886 - $205,550	4,166 Added 11.59%	40,105 $1.82 Million
Q1 2019 May 08, 2019	BUY	$45.12 - $53.8 $1.62 Million - $1.93 Million	35,939 New	35,939 $1.72 Million
Q4 2018 Feb 04, 2019	SELL	$48.76 - $63.23 $479,359 - $621,614	-9,831 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $449,908 - $507,462	8,152 Added 485.53%	9,831 $453,000
Q2 2018 Aug 09, 2018	BUY	$50.53 - $62.98 $22,687 - $28,278	449 Added 36.5%	1,679 $93,000
Q1 2018 May 15, 2018	SELL	$59.92 - $68.98 $24,267 - $27,936	-405 Reduced 24.77%	1,230 $78,000
Q4 2017 Feb 12, 2018	BUY	$59.94 - $65.35 $98,001 - $106,847	1,635	1,635 $100,000

2,403

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $114B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Blackhawk Capital Partners Llc., based on Form 13F filings with the SEC.

Stay updated on Blackhawk Capital Partners Llc. with notifications on news.